Samuel Hund's Contact Details

Samuel Hund's Company Details

Cerebroscope

Pittsburgh, PA, US • 5 - 9 Employees
Medical Equipment

CerebroScope's mission is to design, build, validate, and market easy-to-use devices for monitoring brain-damaging electrical tsunami's (called cortical spreading depressions, CSDs) in the neuro-intensive care unit. CerebroScope's 2-year NIH SBIR will enable the design and development of a proof-of-concept prototype system that once validated in acute brain injury will have a major impact in its treatment. Upon successful completion of Phase I, CerebroScope will be eligible to apply for Phase II funding for further commercialization. Phase II will also test whether use could be expanded to include other conditions where CSD is known to occur, such as migraine aura, and likely to occur, such as concussion, with the additional goal to provide a clear, definitive, and immediate diagnosis of athletic and battlefield concussion. The key features of our proposed device are: 1) It detects CSD from the scalp, whereas previously CSD has only been observed (in acute brain injury) with electrodes on the brain surface. 2) For acute brain injury, the device can be used to develop therapeutics based on stopping CSD, as each repetitive CSD kills more brain. 3) For migraine aura, the device can be used to evaluate existing and future therapeutics that are based on stopping CSD before the progression to migraine pain. 4) For concussion the device: a) detects an actual brain event, rather than what the brain does to the rest of the body, clearly differentiating it from most, if not all, current concussion assessment methods that depend on post-concussion symptoms; and b) provides an immediate result during the short period from 5 to 50 minutes after a concussive head hit or blast injury.